Cardiac myosin inhibitors
Drugs such as mavacamten and aficamten for hypertrophic cardiomyopathy.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 8, 7, 11, 14, 16.
New guidelines and consensus this year
- EJHF expert consensus statement on the diagnosis and management of hypertrophic cardiomyopathyEur J Heart Fail2026 May 11
All papers from the last 12 months
264 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Real-world mavacamten: What SWISS-MAVA addsInt J Cardiol2026 Dec 1PMID 42660320
- A global model for symptomatic obstructive hypertrophic cardiomyopathy to assess the cost-effectiveness of mavacamten: results from a Dutch societal perspectiveJ Med Econ2026 DecPMID 42258343
- Effect of cardiac myosin inhibitors on cardiac structure and myocardial fibrosis in obstructive hypertrophic cardiomyopathy: a meta-analysis of cardiac magnetic resonance outcomesClin Radiol2026 NovPMID 42715826Meta-analysis
- Development and validation of an HPLC-MS/MS method for the quantification of Aficamten in human plasma and urine and application to a clinical pharmacokinetic studyJ Chromatogr B Analyt Technol Biomed Life Sci2026 Nov 1PMID 42623945
- Real-world effectiveness, response patterns and clinical implementation of Mavacamten in obstructive hypertrophic cardiomyopathy: Insights from the SWISS-MAVA cohortInt J Cardiol2026 Nov 1PMID 42501898
- Beyond the Gradient: Patient-Reported Outcomes with Aficamten in Obstructive Hypertrophic CardiomyopathyEur J Heart Fail2026 Oct 17PMID 42888171
- Hypertension management in obstructive hypertrophic cardiomyopathy patients treated with cardiac myosin inhibitors - real world dataInt J Cardiol2026 Oct 15PMID 42402257
- Structure-property Relationships Reported for the New Drugs Approved in 2025Mini Rev Med Chem2026 Oct 12PMID 42872654
- Left Ventricular Structural, Physiological, and Transcriptomic Abnormalities in a Novel Porcine Hypertrophic Cardiomyopathy ModelJACC Basic Transl Sci2026 Oct 9PMID 42854668
- Mitral Papillary Muscle Papillary Fibroelastoma in Obstructive Hypertrophic Cardiomyopathy: A Surgically Treated Embolic SourceJACC Case Rep2026 Oct 7PMID 42847571
More cardiology trends
All specialties →AI-enabled ECG
Artificial intelligence applied to electrocardiograms to detect or predict disease.
TAVR / TAVI
Transcatheter aortic valve replacement for aortic stenosis.
SGLT2 inhibitors in heart failure
Use of SGLT2 inhibitors such as dapagliflozin and empagliflozin across heart failure types.
Remote cardiac rehabilitation
Cardiac rehabilitation delivered at home or through digital tools.
Key point: Exercise-based telerehabilitation probably improves cardiorespiratory fitness in adults with CVD but provides no convincing evidence of an antihypertensive effect.
Inclisiran
An siRNA drug that lowers LDL cholesterol by reducing PCSK9 production in the liver.
Key point: Inclisiran achieves similar LDL-C reductions with biannual dosing, potentially improving adherence, though cardiovascular outcome data are pending.
Factor XI inhibitors
A newer class of anticoagulants that target factor XI or XIa.
Key point: Adding an FXIa inhibitor to standard antiplatelet therapy after acute noncardioembolic ischemic stroke or TIA reduces stroke recurrence without evidence of increased bleeding risk.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
mavacamten[tiab] OR aficamten[tiab] OR "cardiac myosin inhibitor"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.